Immunotherapy Efficacy for EGFR L858R-Mutated Lung Cancer: Meta-Analysis of 17 Studies

A meta-analysis dataset of 17 studies involving 1,154 patients with TKI-resistant, EGFR L858R-mutated non-small cell lung cancer. It evaluates the efficacy of immune checkpoint inhibitors, comparing monotherapy and combination treatments against chemotherapy based on progression-free survival, objective response rate, and overall survival. The dataset was uploaded by Peipei Zhang and last updated on April 10, 2026.

Use Cases

• Compare progression-free survival (PFS) outcomes for different immunotherapy regimens based on hazard ratios.
• Analyze objective response rate (ORR) trends between monotherapy and combination therapies.
• Validate meta-analysis findings on the efficacy of ICI plus anti-angiogenic agents plus chemotherapy regimens.
• Assess overall survival (OS) data for ICI treatments versus chemotherapy in the post-TKI setting.

Strengths

• Includes data from 17 studies with 1,154 patients, providing a substantive sample for analysis.
• Stratifies analysis by study design (randomized controlled trials vs. single-arm studies) and treatment modality.
• Reports specific hazard ratios and confidence intervals for key endpoints like PFS and OS.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data may reflect publication or selection bias inherent to the systematic review methodology.
• The dataset is small (2.8 MB), which may limit the complexity of analyses possible.

Provenance

Source

figshare, uploaded by Peipei Zhang.

Collection Method

Systematic review and meta-analysis of studies from PubMed, EMBASE, Cochrane, and Web of Science up to January 1, 2026.

Time Range

Studies included up to January 1, 2026.

Freshness

Last updated 2026-04-10 05:57:52; freshness should be verified.

Geography

null